Diversify Advisory Services LLC Sells 3,074 Shares of Novo Nordisk A/S (NYSE:NVO)

Diversify Advisory Services LLC cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 22.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,849 shares of the company’s stock after selling 3,074 shares during the period. Diversify Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $936,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Natixis Advisors LLC grew its position in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC grew its holdings in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares in the last quarter. Talbot Financial LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $4,066,000. Versant Capital Management Inc purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $86,000. Finally, Zions Bancorporation N.A. boosted its position in shares of Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after acquiring an additional 6,726 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $78.74 on Tuesday. The stock’s 50-day moving average is $97.76 and its 200 day moving average is $116.89. The stock has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.